Collaboration, License, Co-Promotion and Other Commercial Agreements - China, Hong Kong and Macau (Details) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Sep. 30, 2019 USD ($) installment	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)
Collaboration, License and Co-Promotion Agreements
Revenue		$ 89,432	$ 102,215	$ 169,375	$ 170,945
Collaborative arrangements revenue
Collaboration, License and Co-Promotion Agreements
Revenue		89,423	77,322	163,868	143,474
Sale of active pharmaceutical ingredient
Collaboration, License and Co-Promotion Agreements
Revenue		9	24,893	5,507	27,471
AstraZeneca | China, Hong Kong, and Macau | Collaborative arrangements revenue
Collaboration, License and Co-Promotion Agreements
Collaborative arrangement, significant financing component, transaction price	$ 2,600
Collaborative arrangement, expected interest income		2,600		2,600
AstraZeneca | China, Hong Kong, and Macau | Collaborative arrangement, collaboration and license agreements
Collaboration, License and Co-Promotion Agreements
Revenue		187		519
AstraZeneca | China, Hong Kong, and Macau | Collaborative arrangement, collaboration agreements
Collaboration, License and Co-Promotion Agreements
Milestone payment to be received by company upon milestone achievement	90,000
Amount of non-contingent arrangement consideration	$ 35,000
Non-contingent consideration installments | installment	3
Percentage of tiered royalties	20.00%
Revenue		32,400
Interest income		200		400
AstraZeneca | China, Hong Kong, and Macau | Collaborative arrangement, transition services agreement
Collaboration, License and Co-Promotion Agreements
Regulatory and administrative services initial term	2 years
AstraZeneca | China, Hong Kong, and Macau | Sale of active pharmaceutical ingredient
Collaboration, License and Co-Promotion Agreements
Revenue		9		$ 5,507
AstraZeneca | China, Hong Kong, and Macau | Commercialization milestone | Collaborative arrangement, collaboration agreements
Collaboration, License and Co-Promotion Agreements
Percentage of net loss from commercialization (as a percent)				55.00%
AstraZeneca Service Agreement | China, Hong Kong, and Macau | Collaborative arrangement, collaboration agreements
Collaboration, License and Co-Promotion Agreements
Pre-launch commercial services and supply chain services			$ 300		$ 500
Revenue		$ 200		$ 400
AstraZeneca Service Agreement | China, Hong Kong, and Macau | Royalty
Collaboration, License and Co-Promotion Agreements
Revenue				$ 200